Zhejiang Wenda Pharma reports Phase II data for NHWD-870 HCl

Zhejiang Wenda Pharmaceutical Technology presented Phase II clinical trial data for NHWD-870 HCl at the 2026 ESMO Annual Meeting. The study evaluated the oral BET inhibitor in Chinese patients diagnosed with advanced NUT carcinoma, a rare and aggressive malignancy with limited standard-of-care options.

The trial aimed to measure the efficacy and safety profile of the compound in patients who have exhausted existing therapeutic avenues. By inhibiting BET proteins, the drug targets specific pathways associated with the proliferation of NUT-carcinoma cells.

The reported data provides a foundation for the company's regulatory and development strategy. Zhejiang Wenda Pharma indicated that the findings support further clinical investigation to determine the long-term potential of the therapy.